论文部分内容阅读
目的:观察头孢哌酮钠舒巴坦钠联合喹诺酮类药物治疗慢性阻塞性肺疾病急性加重期患者的临床疗效并进行探讨。方法:选择慢阻肺急性加重期病人78例做为研究病例,随机分为试验组39例与对照组39例,对照组病例接受常规治疗,抗感染药物选择单用头孢哌酮钠舒巴坦钠,试验组患者则在对照组病例治疗方案的基础上,联合喹诺酮类药物,对两组入选病例治疗后的临床治疗总有效率、药物相关不良反应的发生率实施对照分析。结果:两组入选病例治疗后的临床治疗总有效率的比较存在显著性差异,(P<0.05),两组病例的药物相关不良反应的比较无显著性差异,(P>0.05)。结论:对慢性阻塞性肺疾病急性加重期患者采用头孢哌酮钠舒巴坦钠与喹诺酮类联合治疗的抗感染方案,可提高临床治疗总有效率,且不增加药物相关不良反应的出现机率。
Objective: To observe the clinical efficacy of cefoperazone sodium and sulbactam combined with quinolones in patients with acute exacerbation of chronic obstructive pulmonary disease. Methods: Seventy-eight patients with acute exacerbation of chronic obstructive pulmonary disease (COPD) were enrolled in this study. They were randomly divided into experimental group (39 cases) and control group (39 cases). Patients in the control group received routine treatment. Anti-infectives were given cefoperazone sodium and sulbactam sodium alone. The patients in the control group were treated with quinolones on the basis of the control group. The total effective rate of clinical treatment and the incidence of adverse drug reactions were compared between the two groups. Results: There was a significant difference in the total effective rate of clinical treatment between the two groups (P <0.05). There was no significant difference in the drug-related adverse reactions between the two groups (P> 0.05). Conclusion: The anti-infectives of cefoperazone sodium and sulbactam combined with quinolones in patients with acute exacerbation of chronic obstructive pulmonary disease can improve the total effective rate of clinical treatment without increasing the incidence of drug-related adverse reactions.